Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Cellectis of France Surrenders Claim for Damages Against Shionogi
February 22, 2012
- DSP Obtains Approval for Myslee Generic, Boosting Efforts to Strengthen CNS Field
February 21, 2012
- Pfizer Japan, DSP Apply for Pediatric Indication for Norvasc and Amlodin Based on Data from Public Domain
February 21, 2012
- Astellas, SKK Announce Alliance in Field of Kidney Diseases
February 21, 2012
- Nichi-Iko Makes Yakuhan Subsidiary to Expand Disinfectant Lineup
February 21, 2012
- Kowa Launches Livalo in Mexico through Eli Lilly
February 21, 2012
- Sales of DPP-4 Inhibitors Reach ¥100 Billion Level, Antidiabetic Drugs Show Double-Digit Growth: IMS Japan
February 20, 2012
- Pfizer Japan Ranked No. 1 as Promotion Company: IMS Japan
February 20, 2012
- Qol President Nakamura Says “Proactive Cooperation” Needed for Distribution Improvement
February 20, 2012
- Daiichi Sankyo, Roche Announce Approval of Malignant Melanoma Treatment Vemurafenib in EU
February 20, 2012
- Diabetes Treatments: Their Development and Market
February 20, 2012
- With Upcoming Price Cuts, Nursing Homes Present Opportunity for Makers of Generic AD Treatments
February 20, 2012
- Fuso Acquires Exclusive Domestic Marketing Rights to Mucus Bulging Agent
February 20, 2012
- 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
February 17, 2012
- Qol Expects to Clear “30%” Generic Dispensing Mark Around October
February 17, 2012
- 40% of Doctors Prescribe Existing Drugs Until New Drug Information Is Clarified: Survey
February 17, 2012
- Daiichi Sankyo, Pfizer Obtain Approval for Their Competition Generics for June Listing
February 17, 2012
- Drugstore Chains to Appeal Directly to Public in Support of “Dispensing Point” Services
February 17, 2012
- EC Approves Add’l Indication of CHF for Ion Channel Inhibitor Ivabradine: Ono
February 17, 2012
- Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic Ahead of Competitors
February 16, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…